| Name | Title | Contact Details |
|---|---|---|
Peter Wang |
Chief Technology Officer | Profile |
Sansum Medical Research Institute is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The University of Maryland Medical System (UMMS) is a university-based regional health care system focused on serving the health care needs of Maryland. We bring innovation, discovery and research to the care we provide all while educating the state`s future physicians and health care professionals through our partnership with the University of Maryland School of Medicine and the UM Schools of Nursing, Pharmacy, Social Work and Dentistry in Baltimore. As one of the largest private employers in the state, the health system`s 25,000 employees and 4,000 affiliated physicians provide primary and specialty care in more than 150 locations and at 13 hospitals. UMMS` flagship academic campus, the University of Maryland Medical Center in Baltimore, is recognized regionally and nationally for excellence and innovation in specialized care. Our acute care and specialty rehabilitation hospitals serve urban, suburban and rural communities and are located in 13 counties across the state. In addition, UMMS operates health insurance plans serving Medicare and Medicaid members.
Nueterra Capital is a private equity investment and advisory firm with an exclusive focus on healthcare. Leveraging a deep understanding of key industry drivers, Nueterra Capital invests in entrepreneurs with innovative minds, while providing professional expertise and back office resources to improve their bottom line performance and drive growth. Nueterra Capital has invested in hundreds of new ventures and continuously delivers the resources and strategic direction that allow our partners to advance and improve every aspect of healthcare.
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
Mousera is accelerating medical advancement by bringing 21st century technology into living systems research. We`re currently recruiting in software, machine learning, computer vision, distributed systems, and user experience, while looking for heads of our preclinical and customer organizations. Contact me to find out more.